NO942033L - Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator - Google Patents

Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator

Info

Publication number
NO942033L
NO942033L NO942033A NO942033A NO942033L NO 942033 L NO942033 L NO 942033L NO 942033 A NO942033 A NO 942033A NO 942033 A NO942033 A NO 942033A NO 942033 L NO942033 L NO 942033L
Authority
NO
Norway
Prior art keywords
preparation
stabilizer
factor viii
coagulation factor
surfactant
Prior art date
Application number
NO942033A
Other languages
English (en)
Other versions
NO942033D0 (no
Inventor
Thomas Osterberg
Angelica Fatouros
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202878A external-priority patent/SE9202878D0/xx
Priority claimed from SE9301580A external-priority patent/SE9301580D0/xx
Priority claimed from SE9302006A external-priority patent/SE9302006D0/xx
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO942033D0 publication Critical patent/NO942033D0/no
Publication of NO942033L publication Critical patent/NO942033L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Et nytt preparat omfattende koagulasjonsfaktor VIII og et ikke- ionisk overflateaktivt middel, slik som blokk-kopolymerer, f.eks. polyoksamerer eller polyoksyetylen(20)sorbitan-fett- syreestere, f.eks. polysorbat 20 eller polysorbat 80, som stabilisator. Preparatet kan også omfatte natrium- klorid, kalsiumklorid, L-histidin og/eller sukkere eller sukkeralkoholer. Anvendelse av et ikke-ionisk overflate- aktivt middel som stabilisator for et preparat omfattende koagulasjonsfaktor VIII er også beskrevet.
NO942033A 1992-10-02 1994-06-01 Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator NO942033L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9202878A SE9202878D0 (sv) 1992-10-02 1992-10-02 Protein formulation
SE9301580A SE9301580D0 (sv) 1993-05-07 1993-05-07 Protein formulation
SE9302006A SE9302006D0 (sv) 1992-10-02 1993-06-11 Protein formulation
PCT/SE1993/000793 WO1994007510A1 (en) 1992-10-02 1993-10-01 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Publications (2)

Publication Number Publication Date
NO942033D0 NO942033D0 (no) 1994-06-01
NO942033L true NO942033L (no) 1994-06-01

Family

ID=27355693

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942033A NO942033L (no) 1992-10-02 1994-06-01 Preparat omfattende koagulasjonsfaktor VIII, fremgangsmåte for fremstilling derav samt anvendelse av et overflateaktivt middel som stabilisator

Country Status (19)

Country Link
US (2) US5733873A (no)
EP (3) EP0627924B1 (no)
JP (1) JP3905921B2 (no)
KR (1) KR100303872B1 (no)
AT (2) ATE198277T1 (no)
CA (1) CA2124690C (no)
CZ (1) CZ290342B6 (no)
DE (2) DE69329795T2 (no)
DK (1) DK0627924T3 (no)
ES (1) ES2154650T3 (no)
FI (1) FI111443B (no)
GR (1) GR3035472T3 (no)
HU (2) HU220194B (no)
MX (1) MX9306133A (no)
NO (1) NO942033L (no)
NZ (1) NZ256921A (no)
PT (1) PT627924E (no)
SK (1) SK282483B6 (no)
WO (1) WO1994007510A1 (no)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2634663C (en) * 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
ATE310533T1 (de) 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP2289547B1 (en) 2003-09-12 2015-12-16 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
RU2440810C2 (ru) 2005-04-28 2012-01-27 Ново Нордиск Хелс Кеа Аг Закрытый контейнер, содержащий активированный полипептид фактора vii, способы его получения и набор и способ применения набора
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
CA2709890A1 (en) 2007-12-27 2009-07-09 Andre Giovagnoli Cell culture processes
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
CN107050437A (zh) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
AU2009303368B2 (en) * 2008-10-15 2012-04-05 Takeda Pharmaceutical Company Limited Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
ES2669020T3 (es) 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
JP6043627B2 (ja) 2009-06-25 2016-12-14 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アルブミン非含有ボツリヌス毒素製剤
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) * 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
AU2011282571C1 (en) 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
EP2651433A1 (en) * 2010-12-16 2013-10-23 Novo Nordisk A/S Aqueous factor viii solution
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
JP2017509659A (ja) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ 低糖−低グリシンの安定な第ｖｉｉｉ因子製剤
KR20160146763A (ko) * 2014-04-01 2016-12-21 어드밴텍 바이오사이언스 파마큐티카 엘티디에이 부형제로서 칼슘이 첨가되지 않은 factor viii의 안정화
US20170209546A1 (en) * 2014-07-25 2017-07-27 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
JP6516829B2 (ja) * 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
KR20180079384A (ko) * 2015-11-05 2018-07-10 노보 노르디스크 에이/에스 Fviii 제제
EP3167877A1 (en) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
MX2018006738A (es) 2015-12-03 2018-09-21 Baxalta Inc Factor viii con propiedades de semivida extendida y union reducida al ligando.
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115768787A (zh) * 2020-05-22 2023-03-07 阿法姆海外股份有限公司 IL1-R1衍生的IL-1β抑制剂及其用途
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
KR20240024949A (ko) * 2021-06-23 2024-02-26 바이오버라티브 테라퓨틱스 인크. 인자 viii 키메라 단백질의 제형 및 이의 용도
CN118103034A (zh) * 2021-10-15 2024-05-28 比奥维拉迪维治疗股份有限公司 因子viii嵌合蛋白的配制品及其用途
CN115554418B (zh) * 2022-11-22 2023-04-14 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
EP0381345B1 (en) * 1989-01-30 1994-07-13 Corint, Ltd. Aqueous liquid desmopressin-CMC pharmaceutical composition
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer

Also Published As

Publication number Publication date
AU677797B2 (en) 1997-05-08
DE69333974T2 (de) 2006-08-03
SK65994A3 (en) 1995-03-08
JPH07501560A (ja) 1995-02-16
US5919766A (en) 1999-07-06
NZ256921A (en) 1996-05-28
EP0627924A1 (en) 1994-12-14
NO942033D0 (no) 1994-06-01
CA2124690C (en) 2007-09-11
ATE316981T1 (de) 2006-02-15
JP3905921B2 (ja) 2007-04-18
DE69333974D1 (de) 2006-04-13
ES2154650T3 (es) 2001-04-16
DE69329795D1 (de) 2001-02-01
CZ290342B6 (cs) 2002-07-17
EP1652534A2 (en) 2006-05-03
CA2124690A1 (en) 1994-04-14
AU5288393A (en) 1994-04-26
GR3035472T3 (en) 2001-05-31
US5733873A (en) 1998-03-31
DE69329795T2 (de) 2001-07-05
SK282483B6 (sk) 2002-02-05
HU220194B (hu) 2001-11-28
WO1994007510A1 (en) 1994-04-14
HUT70330A (en) 1995-09-28
HU9401382D0 (en) 1994-08-29
ATE198277T1 (de) 2001-01-15
FI942573A0 (fi) 1994-06-01
HU211670A9 (en) 1995-12-28
FI111443B (fi) 2003-07-31
DK0627924T3 (da) 2001-04-30
EP1016673B1 (en) 2006-02-01
CZ132894A3 (en) 1994-11-16
EP1016673A1 (en) 2000-07-05
EP0627924B1 (en) 2000-12-27
FI942573L (fi) 1994-06-01
MX9306133A (es) 1994-04-29
EP1652534A3 (en) 2007-05-02
KR100303872B1 (ko) 2001-11-22
PT627924E (pt) 2001-05-31

Similar Documents

Publication Publication Date Title
CA2124690A1 (en) Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
ES2190425T3 (es) Procedimiento para la preparacion de alaninato de (n-fenilacetil-n-2,6-xilil)metilo.
CA2021581A1 (en) Improved stable coagulation controls
ES2194013T3 (es) Plaquetas de sangre humana de secado fijo farmaceuticamente aceptables.
NO167705C (no) Fremgangsmaate for fremstilling av et fortykningsmiddel for matvarer og for.
NO960049D0 (no) Fremstilling og stabilisering av celler
ES2080497T3 (es) Bloques para la limpieza de inodoros.
IT8620939A0 (it) Processo per la preparazione di (2,2)-paraciclofano e suoi derivati.
AU5787490A (en) Process for reducing the crystal size of ondanestron hydrochloride dihydrate
CA2177997A1 (en) Enzyme stabilization by block-copolymers
NO180701C (no) Anvendelse av en insekticid og/eller akaricid vannblandbar formulering for skadedyrbekjempelse
AU698744B2 (en) Oil-in-water emulsions
NO893142L (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
NO904794L (no) Interpolymere latekser fra estere av metakrylsyre og vinylestere av forgrenede karboksylsyrer, og fremstilling av slike latekser.
NO875239D0 (no) Fremgangsmaate ved spalting av 1,4-dihydropyridinderivater i optisk aktive isomerer.
JPS57156407A (en) Insecticide and acaricide containing trifluoromethanesulfon anilide derivative as an active ingredient
IT1147839B (it) Derivati di acido ciclopropan carbossilico per la lotta contro i parassiti,composizioni che li contengono e procedimento per la loro preparazione
NO943699L (no) Fremgangsmåte for kontinuerlig fremstilling av en fast matvarematriks
NO158984C (no) Anvendelse av (e)-beta-farnesen i vaeskeform eller av en (e)-beta-farnesen-inneholdende vaeske som et kontaktinsekticidmot bladlus.
NO904793L (no) Interpolymere latekser fra estere av metakrylsyre og vinylestere av forgrenede karboksylsyrer, samt fremgangsmaate for fremstilling av slike latekser.
HUT47375A (en) Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components
IT8247871A0 (it) Derivati di carbammati, composizioni insetticide, acaricide o nematocide che li contengono e procedimento per la loro produzione ed applicazione
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
NO965267D0 (no) Glucuronyl-forbindelser, og framgangsmåte for framstilling av samme
AU553922B2 (en) Poly-bis-triazinylimides as light stabilizer for polymers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application